Section 3 of 6
Product information and disease description
205 evidence topics · 82 sources
Product description
Phase of product development
Investigational status and development phase
Regulatory status: Submission planned; NDA submission anticipated in 2028
Launch
No evidence found.
Anticipated milestones: phase 3 topline data and study completion dates
Development history: phase 1/2 study start and status
Development history: phase 3 and extension study start
FDA orphan drug designation
FDA Fast Track designation
FDA feedback on the phase 3 design
Regulatory designations outside the United States
No evidence found.
Patent protection
Product information
Generic, brand name and therapeutic class of product
Manufacturer: ADARx Pharmaceuticals
Ownership
Nonproprietary name, development code, and therapeutic class
Brand name
No evidence found.
Dosage forms and strengths
Investigational drug substance and placebo
Phase 3 doses and injection volumes
| Arm | Quoted dose and volume |
|---|---|
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo matched to the 6-month regimen | “Placebo (1.5 ml) n=15” |
| Placebo matched to the 3-month regimen | “Placebo (1.2 ml) n=15” |
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO International Nonproprietary Name functional class
AHFS classification
No evidence found.
Indication
Indication named in the FDA Fast Track designation
Indication named in the FDA orphan drug designation
Investigational population in the phase 3 trial
Pharmacology
Mechanism of action
Prekallikrein mRNA degradation in the liver
RNA interference: RISC-mediated cleavage of target mRNA
Congress reports: prekallikrein mRNA cleavage and bradykinin generation
Molecular structure and hepatic targeting
“GalNAc3-conjugated siRNA targeting hepatic prekallikrein mRNA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It selectively targets hepatic prekallikrein mRNA to reduce prekallikrein production.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic targeting for novel prophylactic therapies: review
Pharmacodynamics
Phase 1 interim: nadir prekallikrein by weight-based dose
Phase 1: 6 mg/kg single dose
Phase 1: 300 mg (plus or minus 25 mg) single fixed dose, prospectus
Phase 1: 300 mg single dose, congress reports
Phase 1: 300 mg single dose, sponsor press release
Phase 1: 300 mg dose cohort as attributed in the November 2026 corporate presentation
Phase 2a: prekallikrein reduction in participants with HAE compared with healthy volunteers
Phase 2a: prekallikrein suppression threshold associated with absence of attacks
Preclinical studies: serum prekallikrein after a single 4 mg/kg dose in nonhuman primates
Preclinical studies: prekallikrein suppression at 200 mg/kg in nonhuman primates
Preclinical studies: projected dosing interval from nonhuman primate data
Nonclinical toxicology: nonhuman primates and rabbits
Nonclinical toxicology: off-target effects observed in rats
Pharmacokinetics
Plasma exposure and half-life: phase 1 and phase 2
Short plasma circulation relative to pharmacodynamic duration
Planned pharmacokinetic parameters: phase 1/2 registry record
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Pediatric patients: trial enrollment limited to adults
Older adults: phase 1 age range
Pregnancy and lactation: exclusion from the phase 1/2 study
Pregnancy and fertility: nonclinical reproductive studies
Drug/Drug, drug/disease interactions
Effects of other drugs on Onvuzosiran
No evidence found.
Effects of Onvuzosiran on other drugs
No evidence found.
Dosing and administration
Dosage
Phase 2a doses and dose selection for phase 3
Dosing in the phase 3 extension study
Administration
Route and dosing interval
Phase 3 visit schedule
Access and distribution
Manufacturing and supply
Continued investigational access after the phase 3 trial
Co-prescribed/Concomitant therapies
STOP-HAE: access to acute on-demand therapy
STOP-HAE: washout of long-term prophylaxis
Phase 1/2 study, HAE cohort: acute therapy and prior prophylaxis
Phase 3 extension study: access to acute therapy
Effect of Onvuzosiran on quality measures
No evidence found.
Product comparison
Donidalorsen: same target, different oligonucleotide mechanism
Donidalorsen: plasma prekallikrein reduction in OASIS-HAE
Donidalorsen: attack-free rate and dosing frequency as described by the sponsor of onvuzosiran
Donidalorsen: mean attack rate per four weeks in OASIS-HAE
| Treatment | Attack rate |
|---|---|
| Donidalorsen every four weeks | “0.44”View highlighted excerpt for this quote |
| Donidalorsen every eight weeks | “1.02”View highlighted excerpt for this quote |
| Placebo | “2.26”View highlighted excerpt for this quote |
Approved prophylactic agents: limitations described by the sponsor of onvuzosiran
Competing prekallikrein siRNA BW-20805: phase 1 in healthy volunteers
Competing prekallikrein siRNA BW-20805: phase 2 in participants with HAE
Lonvoguran ziclumeran: KLKB1 gene knockout
Network meta-analysis of approved prophylactic agents: time-normalized attack rate
“Additional relative effect estimates showed a statistically significant reduction in the rate of attacks for garadacimab compared with every treatment other than lanadelumab 300 Q2W (Fig. 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lanadelumab 300 Q2W showed statistically significant reductions compared with lanadelumab 300 Q4W, berotralstat, and placebo (Fig. 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | Probability of being best (%) | SUCRA (%) |
|---|---|---|
| Garadacimab 200 mg once monthly | “73”View highlighted excerpt for this quote | “94”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 2 weeks | “26”View highlighted excerpt for this quote | “83”View highlighted excerpt for this quote |
| Subcutaneous C1INH 60 IU/kg twice weekly | “1”View highlighted excerpt for this quote | “62”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 4 weeks | “0”View highlighted excerpt for this quote | “40”View highlighted excerpt for this quote |
| Berotralstat 150 mg once daily | “0”View highlighted excerpt for this quote | “20”View highlighted excerpt for this quote |
Network meta-analysis of approved prophylactic agents: attack-free participants
“The fixed-effect model showed that four active treatments, garadacimab, lanadelumab 300 Q2W, lanadelumab 300 Q4W, and subcutaneous C1INH, statistically significantly increased the proportion of attack-free patients compared with placebo (Fig. 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional relative effect estimates between the active treatments did not demonstrate statistically significant results (Fig. 10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of lanadelumab and berotralstat: attack rate per 28 days
“In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Comparison | Rate ratio (95% CI); p-value |
|---|---|
| Lanadelumab 300 mg every 2 weeks vs berotralstat 150 mg once daily | “0.23 (0.10, 0.55); p = 0.0009”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 2 weeks vs C1-INH 1000 IU twice weekly | “0.27 (0.11, 0.64); p = 0.0032”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 2 weeks vs placebo | “0.13 (0.06, 0.29); p < 0.0001”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 4 weeks vs berotralstat 150 mg once daily | “0.48 (0.25, 0.94); p = 0.0311”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 4 weeks vs placebo | “0.27 (0.15, 0.47); p < 0.0001”View highlighted excerpt for this quote |
Cross-trial comparison limitations
“Following the assessment of NMA feasibility, residual heterogeneity between trials may have persisted, despite our best efforts to minimize bias by excluding insufficiently similar trials and/or trial data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All trials were placebo controlled, rather than head-to-head, which further simplified network structures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These network characteristics increase the potential for biased treatment effect estimates, which limits the robustness of the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Definition: recurrent bradykinin-mediated angioedema
“Angioedema is a localized, self-limiting, asymmetric, and disfiguring non-inflammatory edema of the subcutaneous and submucosal tissues that arises because of increased vascular permeability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE comprises a group of genetic disorders characterized by recurrent episodes of angioedema, inherited across generations and typically mediated by bradykinin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classification: HAE with C1-INH deficiency (types 1 and 2) and HAE with normal C1-INH
“HAE (ORPHA:91378, OMIM: PS106100) is most commonly caused by a deficiency of C1 inhibitor (C1-INH), which can be confirmed through biochemical and genetic testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is subclassified into type 1 HAE (quantitative deficiency) and type 2 HAE (dysfunctional protein).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, in 2000, a new type of HAE was described in patients with normal C1-INH function, a form initially known as HAE type 3 but currently called HAE with normal C1-INH (HAE-nC1-INH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic cause: SERPING1 and F12 variants
Penetrance, transmission risk, and de novo variants
“HAE-C1-INH is an autosomal dominant disorder characterized by high penetrance, with only about 5% of mutation carriers remaining asymptomatic over their lifetime.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of parent–child transmission is 50%, but up to 25% of cases result from de novo genetic mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution of HAE types: Swedish population-based cohort
Epidemiology
Incidence of hereditary angioedema
Annual incidence of diagnosed HAE type 1 and 2: Finnish national register
Incidence of treated HAE: Swedish National Prescribed Drug Register, 2024
Prevalence of hereditary angioedema
Prevalence and incidence: systematic literature review
Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval
Pooled diagnosed annual prevalence by HAE type and by region
United States prevalence of all HAE types: commercial claims database, 2018 to 2020
“No US prevalence for all types of HAE has been estimated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our calculations (which exceed the frequently cited 2:100,000 prevalence for HAE with C1 inhibitor deficiency) afford a real-world projected prevalence encompassing all types of HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide pooled prevalence: systematic review and meta-analysis of 24 studies
“Twenty-four studies from 2000 to 2024 were included in the analysis, describing 11,245 cases of HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled prevalence of HAE was 1.22 cases per 100,000 people (95% confidence interval [CI]: 0.91, 1.53), with lower prevalences reported in Asia and Africa compared to Europe and North America.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HAE type 1 made up most of the cases, with a slight female predominance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of diagnosed HAE type 1 and 2: Finnish national register
Natural history, survival, and mortality
Long-term course: onset age, symptom-free years, and severity by sex
“Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, women had a more severe course of the disease than men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with early onset of clinical symptoms were affected more severely than those with late onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Course of an attack and attack frequency without treatment
“The episodes typically involve nonpruritic, nonpitting swelling that worsens over the first 24 hours and gradually subsides over the next 48 to 72 hours, usually lasting no more than 5–7 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated patients with HAE may experience attacks every 7–14 days on average, although some report attacks as frequently as every 3 days, while others may experience them rarely or never.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality from laryngeal attacks: German cohort of 728 patients
“Of the 214 patients who had died, 70 asphyxiated during a laryngeal attack.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality by asphyxiation was higher in patients with undiagnosed HAE-C1-INH (63 cases) than in patients with diagnosed HAE-C1-INH (7 cases).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality from laryngeal attacks: Brazilian reference-center cohort of 433 patients
“A total of 75 fatal events were evaluated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only 10 of 75 patients were given the diagnosis of HAE before death, and the HAE diagnosis was made after death in 65 of 75 patients using verbal autopsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The final cause of death after the investigation was asphyxiation owing to LE in 39 of 75 (52%) and deaths owing to other causes in 36 of 75 (48%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The life span of patients who died of LE was reduced by 20 years compared with those who died of other causes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality from laryngeal edema: review of 23 real-world studies
“The analyzed studies included 3292 patients and 411 deaths from asphyxia due to laryngeal edema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Death rates from laryngeal edema had an average of one death for every 20 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage among deaths in general associated with laryngeal edema was evaluated in three studies (32.7%, 44.4%, and 56%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States death certificates, 1979 to 2010
“The age-adjusted death rate for hereditary angioedema decreased from 0.28 (95% confidence interval [CI] 0.25-0.32) to 0.06 (95% CI 0.05-0.08) per million persons per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lack of specific coding for acquired angioedema most likely explains the observed association between cancer and hereditary angioedema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Family deaths from HAE attacks: US patient registry
“Morbidity surrogates including emergency department visits, hospitalizations, unnecessary abdominal surgeries, and intubations were strikingly high as was mortality with 36.9% of HAE-C1INH and 15.4% of HAE-nl-C1INH participants reporting family members who died from a HAE attack.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: Swedish population-based cohort
“In the current study, there was no increased risk of death (OR 0.69; 95% CI 0.38–1.26) among HAE patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, the mortality among HAE patients during the last decade seems to be low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rising prevalence attributed to decreased mortality: Finnish national register
Factors associated with in-hospital mortality: US Nationwide Inpatient Sample, 2021
Risk of death from laryngeal edema without a diagnosis
Pathophysiology
Bradykinin generation: activation of prekallikrein to plasma kallikrein
“In HAE-C1-INH, bradykinin is the primary mediator of swelling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This molecule arises from cleavage of high-molecular-weight kininogen by plasma kallikrein, which is activated from prekallikrein by factor XII.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resulting bradykinin nonapeptide increases vascular permeability and induces swelling (angioedema) through a specific receptor, B2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of C1 inhibitor in regulating the kallikrein-kinin system
“C1-INH is a serine protease inhibitor protein synthesized in hepatocytes that is crucial in regulating the plasma kallikrein–kinin system (KKS) and preventing excessive bradykinin production.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE-C1-INH is caused by mutations in SERPING1, which encodes C1-INH, leading to reduced levels or impaired activity of C1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This deficiency in turn leads to uncontrolled activation of the KKS and excessive bradykinin production, with bradykinin acting as the key mediator of the condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bradykinin and vascular permeability
Plasma prekallikrein as the target of onvuzosiran
Diagnosis
Systematic literature review of HAE disease burden: diagnostic delay
Guideline recommendation: initial C1-INH functional assay
“We recommend that all patients for whom HAE is suspected undergo an initial assessment with a C1-INH functional assay, as long as it is performed by a specialized laboratory using an accurate, validated method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the C1-INH functional assay is unavailable or unreliable, the diagnosis can still be confirmed through quantitative C1-INH measurement and/or genetic testing for SERPING1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory findings: C4, C1-INH antigen, and C1-INH function
“C4 levels are low in 90%–95% of patients with HAE-C1-INH during asymptomatic periods and are almost always low during acute attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HAE type 1, C1-INH antigen levels are reduced, whereas in HAE type 2, they are normal or elevated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HAE-C1-INH, functional activity is typically less than 50% of normal levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendations: genetic testing and cascade family testing
“We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend cascade family testing for HAE when an index case is diagnosed, either through C1-INH testing or genetic testing, as appropriate based on age and diagnosis (HAE-C1-INH vs. HAE-nC1-INH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay over time
“Fortunately, diagnostic delay in HAE has declined considerably in the last decades, from an average of 21 years in the 1970s to around 7–10 years currently” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Under 40% of patients receive a diagnosis within 1 to 3 years after symptom onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis and diagnoses preceding HAE: Finnish national register
Clinical presentation - signs and symptoms
Gastrointestinal symptoms: intestinal attacks
Airway symptoms: obstruction risk
Distribution of attacks by site: edema episodes reported by 221 patients
“Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Abdominal and laryngeal involvement: proportion of patients affected
“Abdominal involvement occurs in 70%–90% of all individuals and is associated with high morbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laryngeal involvement, although accounting for less than 1% of all attacks, poses a risk of death and occurs at least once in about half of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Airway symptoms: phases of fatal laryngeal attacks
“Phase 1, the predyspnea phase, lasted on average for 3.7 ± 3.2 hours (range, 0-11 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Phase 2, the dyspnea phase, lasted on average for 41 ± 49 minutes (range, 2 minutes to 4 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prodromal symptoms and erythema marginatum
“Non-specific prodromal symptoms are common and can include anxiety, nausea, paresthesia, and fatigue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One third of patients with HAE, especially children, experience erythema marginatum (a nonpruritic form of flat, figurate erythema) as an initial manifestation, which may mimic the skin lesions of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Cardiovascular, thromboembolic, and autoimmune comorbidity: Swedish population-based cohort
“Increased risk of cardiovascular disease (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.32–2.54), including arterial (OR 6.74; 95% CI 1.89–24.06) and venous thromboembolic disease (OR 4.20; 95% CI 2.42–7.23) as well as hypertension (OR 1.64; 95% CI 1.12–2.39) was seen in HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the risk of autoimmune disease was increased (OR 1.65; 95% CI 1.15–2.35) being particularly pronounced for systemic lupus erythematosus (OR 71.87; 95% CI 8.80–586.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the risk of cancer was not increased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A two-fold higher prevalence of allergy, asthma, and atopic dermatitis was found (OR 2.19; 95% CI 1.60–2.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity associated with attenuated androgen prophylaxis
Composite venous thromboembolism: reanalysis of the Swedish cohort
“Our analysis revealed that individuals with HAE had a significantly increased risk of composite VTE compared to controls (odds ratio 3.57, 95% confidence interval 2.16-5.81, Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, individuals with HAE did not have a significantly increased risk of composite ATE (odds ratio 1.3, 95% confidence interval 0.81-2.09, Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C1INH is a potent inhibitor of plasma kallikrein, which spans the kallikrein kinin pathway and intrinsic coagulation pathway, and the intrinsic coagulation pathway components activated factor XII and activated factor XI” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity compared with the general US population: US patient registry
“Females with HAE-C1INH had a significant increase in the prevalence of depression, sleep disorders, kidney disease, anemia, and hepatitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cardiovascular comorbidities were significantly reduced in the HAE-C1INH group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Consequences of delayed diagnosis
“Delays in HAE diagnosis can lead to serious consequences, including reduced quality of life (QoL), loss of productivity and income, depression, unnecessary medical interventions, increased healthcare costs, and an imminent risk of death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unnecessary abdominal surgeries, such as appendectomies, along with exploratory diagnostic procedures such as colonoscopy, also are frequent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of hereditary angioedema
Humanistic burden and health-related quality of life
Burden of disease in adults: multinational survey
Multinational adult survey: treatment exposure and quality-of-life outcomes
| Measure | Reported result |
|---|---|
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |
Patient preferences for long-term prophylaxis: discrete-choice experiment
Health-related quality of life, depression, and work productivity: US patient survey
“A total of 457 HAE patients responded to the survey (response rate, ∼19%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and depression: health technology assessment background
Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey
“The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden despite current therapies: US adult survey
“A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Preferences for long-term prophylaxis and willingness to switch: US adult survey
“A total of 150 individuals completed the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Route of administration and convenience were more than twice as important as dosing frequency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims
“A total of 328 patients were included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (67%) had ≥1 post-index on-demand therapy claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs with lanadelumab compared with berotralstat: US claims
“Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment costs over time with lanadelumab: US claims
“Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect costs of on-demand treatment alone: US patient survey
“Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual per-patient costs by attack severity before current prophylactic agents: US patient survey
“Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hospital costs account for 67% of direct medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resource use after insurance delays or denials of prophylaxis
“A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five percent of respondents reported more urgent care or emergency department visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of hereditary angioedema on families
Income loss from work missed because of attacks
Caregiver productivity costs: US patient and caregiver survey
“For those respondents who indicated that they were either patients or caregivers or solely caregivers, the fact that they would no longer have to take time off work or could participate in the labor force, or be more productive while at work, accounted for $7630 (14.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Genetic testing: cost and limited routine necessity
Medicare payment rates for complement antigen and functional assays
Approaches to treatment
Current treatment options and standard of care
C1 esterase inhibitors
International/Canadian guideline: first-line long-term prophylaxis options
Subcutaneous plasma-derived C1 inhibitor: indication and dosing
Intravenous plasma-derived C1 inhibitor: indication and dosing
Subcutaneous and intravenous routes: guideline comparison
“SC administration of pdC1-INH results in more consistent plasma C1-INH concentrations than the IV route and mitigates venous access–related complications, such as thrombosis risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When first-line treatments are unavailable, IV pdC1-INH (approved for LTP in some countries) is a second-line option, supported by scientific evidence of its efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, it has disadvantages, such as the need for venous access, high cost, and frequent administrations due to its short half-life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma kallikrein inhibitors
Lanadelumab: indication and dosing interval
Berotralstat: oral prophylaxis and dosing
Lanadelumab and berotralstat: guideline summary of efficacy
“Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be aware of delayed onset of action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bradykinin b2 receptor antagonists
Factor XIIa inhibitors
Garadacimab: mechanism and maintenance dosing
Garadacimab: approved population and administration
Garadacimab: guideline summary of efficacy
“It inhibits activated factor XIIa at the top of the kallikrein-kinin pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 3 Vanguard trial the attack rate was reduced by 87% compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prekallikrein-directed antisense oligonucleotides
Donidalorsen: prophylaxis and dosing interval
Donidalorsen: indication, mechanism, and dosing
Donidalorsen: guideline summary of efficacy by dosing interval
“Donidalorsen is an antisense oligonucleotide that blocks the production of prekallikrein in the liver, which is primarily synthesized in the liver.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy of every 4- and 8-weeks injections was 81% and 55%, respectively, compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of a delay in onset of the donidalorsen, when data were compared to placebo starting at week 5, the 4- and 8-weeks dose reduced attacks by 87% and 60%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attenuated androgens
Second-line position, adverse effects, and monitoring
“We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They cannot be used during pregnancy or in the pediatric and adolescent populations because they interfere with growth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend semi-annual monitoring when using androgens, including a complete blood count, chemistry panel, lipid panel, and routine urinalysis, along with annual liver ultrasound.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antifibrinolytics
Tranexamic acid: reported prophylactic responses in HAE-FXII, HAE-PLG, and HAE with normal C1 inhibitor of unknown cause
Androgens and antifibrinolytics: restriction on first-line use
Plasma replacement
Fresh frozen plasma: fallback for on-demand treatment
Solvent detergent plasma and fresh frozen plasma: third-line on-demand treatment
Progestins
Progestin prophylaxis: variant-specific observational evidence
| Feature | Guideline description |
|---|---|
| Subtype with reported responses | “HAE-FXII” |
| Reported response | “Favourable responses” |
| Evidence for other variants | “limited evidence for other HAE-nC1INH variants.” |
Supportive care and airway management
Supportive care when effective on-demand treatment is not available
Upper airway involvement: guideline recommendations
“We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that airway interventions (intubation, cricothyroidotomy, or tracheotomy) be promptly considered during the initial evaluation of patients presenting with signs of upper airway involvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
- Administration frequency of first-line prophylaxis ranges from twice weekly (subcutaneous plasma-derived C1 inhibitor, every 3 or 4 days) and once daily (oral berotralstat) to every 2 weeks (lanadelumab, with every 4 weeks considered after more than 6 months of good control), monthly after a 400 mg loading dose (garadacimab), and every 4 or 8 weeks (donidalorsen). Intravenous C1 inhibitor requires venous access and has a “high cost” and “frequent administrations due to its short half-life”.
- Attacks “can still occur even in patients under LTP”. Berotralstat achieved an approximately 50% reduction in attack rate in its pivotal trial, and donidalorsen every 4 and 8 weeks reduced attacks by 81% and 55%, respectively, compared with placebo. Berotralstat, lanadelumab, and donidalorsen have a delayed onset of protection.
- In US commercial claims, 55% of patients had refill gaps, discontinued, or switched prophylaxis within a year of initiation, and on-demand treatment use “remained present for over two-thirds of patients”. A second study reported that annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaged more than $200,000 after subcutaneous prophylaxis began.
- No head-to-head trials of prophylactic agents have been published; a Cochrane review stated that this “prevented us from drawing firm conclusions on the relative efficacy of the drugs”, and indirect comparisons favor lanadelumab and C1 inhibitor over berotralstat.
- About 50% of patients receive long-term prophylaxis, even in high-income countries, and the higher costs of newer agents limit their availability.
- Second-line attenuated androgens are associated with virilization in women, dyslipidemia, and hepatotoxicity, cannot be used in pregnancy or in children and adolescents, and require semi-annual laboratory monitoring with annual liver ultrasound; tranexamic acid shows “mediocre efficacy in HAE-C1-INH”.
Attacks during prophylaxis and comparative evidence: guideline statements
“Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although no direct comparisons between therapies have been published, indirect comparisons and a Cochrane analysis favor lanadelumab and C1-INH as LTP over berotralstat in terms of efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uptake of prophylaxis and cost as a barrier to access
“Nevertheless, even with recent advances, LTP is still not the standard of care, even in high-income countries, with only about 50% of patients currently receiving it.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite their greater effectiveness, newer drugs are associated with higher costs that clearly limit their availability, particularly in low- and middle-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delayed onset of protection: pediatric guideline
Persistence, switching, and on-demand use after starting prophylaxis: US claims
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence and persistence after starting targeted prophylaxis: US linked health records and claims
“Primary study measures were adherence, defined as the mean proportion of days covered (PDC), and persistence, defined as having no gap in treatment ≥ 45 days after the LTP initiation date.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The main analysis included 357 patients (90 on berotralstat, 189 lanadelumab, and 78 SC-pdC1-INH).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adherence (mean PDC) was similar between treatments at 0.73, 0.78, and 0.74 for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Proportions of patients persistent on index LTP after 12 months were similar across LTPs: 61%, 58%, and 53% for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
A 2026 guideline (Vázquez et al.) recommends that all patients with HAE be evaluated for long-term prophylaxis at every visit through shared decision-making, and lists subcutaneous plasma-derived C1 inhibitor, lanadelumab, berotralstat, garadacimab, and donidalorsen as first-line options. The 2026 pediatric guideline recommends lanadelumab or plasma-derived C1 inhibitor for children aged between 6 and 12 years, and adds berotralstat and garadacimab for adolescents aged 12 years or older. Both guidelines recommend supplying on-demand treatment for at least 2 attacks during prophylaxis, and the Vázquez et al. guideline recommends management by physicians with expertise in HAE supported by a referral center.
Onvuzosiran is an investigational small interfering RNA and appears in no guideline list of first-line agents. The sponsor is developing it for prevention of HAE attacks as a subcutaneous injection every 3 or 6 months, both intervals being studied in the phase 3 STOP-HAE trial, and a 2025 review describes it as in development for long-term prophylaxis in HAE type I/II. STOP-HAE requires participants to complete any washout of long-term prophylaxis before screening and to have access to an acute therapy, so its results will describe onvuzosiran as the only long-term prophylactic agent, compared with placebo, with on-demand treatment available. The sources do not state whether onvuzosiran would be self-administered or given by a health care professional; the guideline states that self-administration and home therapy are available for current agents including lanadelumab, garadacimab, and donidalorsen.
Other prophylactic agents in late-stage development include navenibart, a plasma kallikrein inhibitor dosed subcutaneously every 3 or 6 months in a phase 3 trial with top-line results expected in Q3 2027; deucrictibant XR, with an NDA submission planned for the first half of 2027; lonvoguran ziclumeran, intended as a single-dose therapy, with a PDUFA target action date of March 10, 2027; and BW-20805, a second prekallikrein-directed siRNA dosed every 12 or 24 weeks in a study of 25 participants with HAE.
Evaluation for long-term prophylaxis: guideline recommendation
“We recommend that all patients with HAE are evaluated for LTP at every visit, with a shared decision-making approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Successful LTP implies full disease control with minimal treatment burden and requires patient adherence, so that a shared decision-making approach is essential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line long-term prophylaxis agents: WAO guideline
Pediatric guideline: criteria and first-line agents by age
“We recommend evaluating frequency and location of angioedema attacks, burden of disease, quality of life, patients' and caregivers' preferences, and availability of medications when considering long‐term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children with hereditary angioedema due to C1 inhibitor deficiency aged between 6 and 12 years, we recommend the use of lanadelumab or plasma‐derived C1 inhibitor as first‐line long‐term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of any of the following treatments: berotralstat or garadacimab or lanadelumab or plasma‐derived C1 inhibitor, as first‐line long‐term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Criteria for starting long-term prophylaxis: health technology assessment
Onvuzosiran in guideline and review discussion of investigational agents
Sponsor-stated intended use and dosing intervals
Sponsor-stated rationale relative to current prophylaxis
Phase 3 trial population: discontinuation of prior prophylaxis
Pipeline: navenibart, long-acting plasma kallikrein inhibitor
“Navenibart, a human monoclonal antibody targeting plasma kallikrein and engineered with Fc region modifications that extend its half-life to approximately 100 days, has advanced into phase 3 clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pipeline: deucrictibant, oral bradykinin B2 receptor antagonist
Pipeline: lonvoguran ziclumeran, in vivo gene editing
Pipeline: BW-20805, prekallikrein-directed siRNA
Heterogeneity of treatment effect
No evidence found.
Care management intervention strategies
US HAEA Medical Advisory Board guidelines: on-demand medication access
On-demand treatment during long-term prophylaxis: guideline recommendations
“We recommend that patients have access to ODT, even while receiving LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients or their caregivers are advised to always carry enough medication to treat at least 2 HAE attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-administration and home therapy
“Self-administration and home therapy are available for all C1-INH products, icatibant, berotralstat, sebetralstat, donidalorsen, garadacimab, and lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients and their caregivers be educated in how to administer ODT, including self-administration with all available formulations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring of disease control with validated instruments
“We recommend that all patients with HAE use validated instruments to assess disease activity, severity, disease control, treatment efficacy, and QoL, and that they undergo regular reassessments to ensure optimal therapeutic management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend evaluating efficacy and safety of the long‐term prophylactic agent in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency at least three and six months after initiation, then at least annually.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.